Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study.

Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total shareholder return of 98.13%. This suggests momentum has been building over a longer horizon as investors react to pipeline updates like the new olezarsen data and recent board changes.

If this kind of pipeline driven story interests you, it can be useful to see what else is moving in similar areas through the 40 healthcare AI stocks.

So with Ionis Pharmaceuticals stock roughly flat in the short term but delivering a very strong 1 year return, and trading below some estimates of intrinsic value, is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 26.6% Undervalued

On the most followed narrative, Ionis Pharmaceuticals' fair value of $100.92 sits well above the recent $74.12 share price, putting the focus firmly on what needs to go right in the pipeline for that gap to close.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

Want to see how this story fits together numerically? The fair value hangs on rapid revenue expansion, a swing from losses to profits, and a premium future earnings multiple. Curious which specific growth, margin, and valuation assumptions need to line up for that $100.92 figure to make sense?

Result: Fair Value of $100.92 (UNDERVALUED)

However, investors in Ionis Pharmaceuticals still need to weigh the concentration of expectations in Tryngolza, as well as the execution risk around upcoming FDA decisions and partner run Phase 3 trials.

Another View: What Ionis Pharmaceuticals' Sales Multiple Is Telling You

While the analyst narrative presents Ionis Pharmaceuticals as materially undervalued against a fair value estimate of $100.92, the current P/S ratio of 11.6x tells a different story. That level is richer than both the US Biotechs industry at 10.8x and the fair ratio of 5.3x, which suggests meaningful valuation risk if sentiment cools or revenue expectations soften.

So which signal should be treated as more important: the discounted cash flow style upside case, or a sales multiple that already reflects a substantial amount of positive expectations?

Next Steps

Seeing mixed signals on Ionis Pharmaceuticals and wondering what matters most for you? Take a closer look at the underlying data now and weigh the 3 key rewards.

Looking for more investment ideas beyond Ionis Pharmaceuticals?

If Ionis Pharmaceuticals has caught your attention, do not stop there. Broadening your watchlist with other focused ideas can help you spot opportunities others miss.

• Target dependable income by reviewing companies screened as potential income anchors through the 8 dividend fortresses.
• Hunt for quality at a discount by scanning stocks highlighted in the 45 high quality undervalued stocks.
• Prioritize resilience by checking companies filtered in the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.